Atalanta aims to create disease-modifying therapies by silencing certain genes in the central nervous system, including in the brain and spinal cord.
The firm will use the funds to further develop its AI-driven image analysis solutions, which extract actionable information from CT, PET, and MRI scans.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback